CTRI/2011/09/002007已完成2 期
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases - Not applicable
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Prostate cancer, breast cancer, renal cell carcinoma or multiple myeloma that has been diagnosed as having metastasized to bone;
- •2.Karnofsky Performance Score greater than equal to 40% at Baseline;
- •3.patients randomized and treated with intravenous study drug in double-blind Study A4091003 (CTRI/2011/05/001754).
- •Note: There is no upper age limit for inclusion criteria in the trial
排除标准
- •1.Patient was withdrawn from Study A4091003 (CTRI/2011/05/001754)for an adverse event or serious adverse event;
- •2.Occurrence of any adverse event or condition during Study A4091003 (CTRI/2011/05/001754)or since termination from that study that, in the opinion of the Investigator, would put the patient at increased safety risk or should exclude the subject from participating in the open-label extension Study A4091029.
研究者
相似试验
已完成
不适用
Open Label Extension In Cancer PatientsPER-021-09PFIZER S.A.,
进行中（未招募）
不适用
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 13.1Level: LLTClassification code 10049038Term: Metastatic bone painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005182-66-ATPfizer Inc 235 East 42nd Street New York, NY 1001758
进行中（未招募）
不适用
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 9.1Level: LLTClassification code 10049038Term: Metastatic bone painEUCTR2008-005182-66-LVPfizer Inc 235 East 42nd Street New York, NY 1001758
进行中（未招募）
1 期
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 9.1Level: LLTClassification code 10049038Term: Metastatic bone painEUCTR2008-005182-66-FRPfizer Inc 235 East 42nd Street New York, NY 1001758
进行中（未招募）
1 期
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 9.1Level: LLTClassification code 10049038Term: Metastatic bone painEUCTR2008-005182-66-HUPfizer Inc 235 East 42nd Street New York, NY 1001760